usana health sciences’ mission is to develop and provide the highest quality, science-based health products, distributed internationally through network marketing, creating a rewarding financial opportunity for our independent associates, shareholders, and employees. we’ve got history. not baggage. we’ve been around since 1992, so we’re experienced (we’ve heard that’s a plus). and we look great for our age. plus, we have substance to go along with our great looks. we’ve got top-notch manufacturing facilities, our own scientists and research and development team, and the highest standards for our nutritional products. we have an award-winning compensation plan and award-winning products. we don’t like to brag, but we come pretty highly recommended. that’s because we got off on the right foot. we were founded by a scientist—not a corporate suit. usana’s founder, myron wentz, is an internationally recognized microbiologist, immunologist, and pioneer in infectious disease diagnosis. but su
Company profile
Ticker
USNA
Exchange
Website
CEO
Kevin Guest
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Curaleaf • Jushi • Ascend Wellness • Trulieve Cannabis • 4Front Ventures • SNDL • Mind Medicine • Glass House Brands • C21 Investments • Mannatech ...
Former names
USANA INC
SEC CIK
Corporate docs
Subsidiaries
USANA Canada • USANA Health Sciences, China, Inc. • USANA Health Sciences, New Zealand, Inc. • International Holdings, Inc. • UHS Essential Health Philippines, Inc. • Pet Lane Inc. • USANA Canada Co. • USANA Australia • USANA Health Sciences (NZ) Corporation • USANA Hong Kong Limited ...
IRS number
870500306
USNA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Key Financial Results & Guidance
6 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Key Financial & Operating Results
24 Oct 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Key Financial & Operating Results
25 Jul 23
8-K/A
Departure of Directors or Certain Officers
12 May 23
Transcripts
USNA
Earnings call transcript
2023 Q4
7 Feb 24
USNA
Earnings call transcript
2023 Q3
25 Oct 23
USNA
Earnings call transcript
2023 Q2
26 Jul 23
USNA
Earnings call transcript
2023 Q1
26 Apr 23
USNA
Earnings call transcript
2022 Q4
8 Feb 23
USNA
Earnings call transcript
2022 Q3
26 Oct 22
USNA
Earnings call transcript
2022 Q2
27 Jul 22
USNA
Earnings call transcript
2022 Q1
27 Apr 22
USNA
Earnings call transcript
2021 Q4
10 Feb 22
USNA
Earnings call transcript
2021 Q3
27 Oct 21
Latest ownership filings
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Kevin Guest
11 Mar 24
4
Walter Noot
11 Mar 24
4
Brent Neidig
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
4
ROBERT A SINNOTT
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
John Turman Fleming
5 Mar 24
4
GILBERT A FULLER
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
94.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 156 |
Opened positions | 11 |
Closed positions | 18 |
Increased positions | 51 |
Reduced positions | 66 |
13F shares | Current |
---|---|
Total value | 588.39 bn |
Total shares | 18.11 mm |
Total puts | 1.50 k |
Total calls | 6.20 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Wentz Myron W | 7.99 mm | $800.81 mm |
BLK Blackrock | 1.85 mm | $108.55 bn |
Vanguard | 1.57 mm | $91.85 bn |
Renaissance Technologies | 1.21 mm | $70.79 bn |
Pzena Investment Management | 787.44 k | $46.15 bn |
Dimensional Fund Advisors | 656.14 k | $38.46 bn |
STT State Street | 427.98 k | $25.08 bn |
MS Morgan Stanley | 273.86 k | $16.05 bn |
Geode Capital Management | 244.72 k | $14.34 bn |
Charles Schwab Investment Management | 213.89 k | $12.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Guest Kevin | Common Stock | Sell | Dispose S | No | No | 49 | 11,011 | 539.54 k | 10,491 |
8 Mar 24 | Noot Walter | Common Stock | Sell | Dispose S | No | No | 49.05 | 5,240 | 257.02 k | 0 |
6 Mar 24 | Neidig Brent | Common Stock | Sell | Dispose S | No | No | 46.999 | 3,810 | 179.07 k | 0 |
5 Mar 24 | Sinnott Robert A | Common Stock | Sell | Dispose S | No | No | 46.555 | 3,945 | 183.66 k | 0 |
4 Mar 24 | Fuller Gilbert A | Common Stock | Sell | Dispose S | No | No | 49.0748 | 491 | 24.10 k | 0 |
News
DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $48
22 Feb 24
Recap: Usana Health Sciences Q4 Earnings
6 Feb 24
Usana Health Sciences Q4 EPS $0.87 Beats $0.52 Estimate, Sales $221.08M Beat $212.82M Estimate
6 Feb 24
Earnings Scheduled For February 6, 2024
6 Feb 24
Earnings Preview: Usana Health Sciences
5 Feb 24
Press releases
Kevin Guest Says Leap Forward on Leap Day
28 Feb 24
USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2023 Results
6 Feb 24
Kevin Guest Calls on All to Connect during February Month of Friendship
1 Feb 24
USANA Manufacturing Facility Receives Coveted GFSI Certification from SQF
25 Jan 24
USANA to Continue Investing in Local Community after Decades-Long Amphitheatre Sponsorship Ends
23 Jan 24